Healthcare Professional Portal
Healthcare Professional Portal
The penultimate webinar in our 2026 Beyond sleepless nights: managing chronic insomnia in adults series, in collaboration with MIMS Learning.
Dr Tim Mercer, GP Partner, based in Wirral, reviews the management options for nocturia in patients with sleep disorders, with particular consideration of the approaches to balancing treatment efficacy and fall risk in vulnerable patients. Dr Mercer will also discuss how QUVIVIQ▼ (daridorexant) can support the management of chronic insomnia in suitable patients.
MIMS WEBINAR SERIES
Join us for this MIMS Learning webinar series focusing on chronic insomnia in adults. Over five webinars throughout 2026, our expert speakers will explore the impact of chronic insomnia in diverse patient populations and discuss diagnostic approaches.
They will also highlight recommendations for chronic insomnia management in clinical practice, including pharmacological interventions such as QUVIVIQ (daridorexant), as well as lifestyle and psychological approaches.
Click the button below to find out more and register via MIMS Learning:
One of our product specialists would be happy to answer your questions.
QUVIVIQ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated June 2024. Accessed July 2024.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
You already have an account?
Register to get access to:
Dr Tim Mercer is a GP Partner based in Wirral with a specialist interest in insomnia, migraine, and what he calls “the heartsink feeling.” He believes sleep is relevant to every condition and has developed practical methods for delivering cognitive behavioural therapy for insomnia (CBT-I) in general practice, alongside careful use of pharmacotherapy. Tim is known for his sincere, patient-centred approach and passion for general practice. Patients describe him as someone who “listens sincerely” and “goes above and beyond” (PSQ, 2025).
He loves his job, his patients, and helping others to love theirs too.
You are being redirected to our partner’s website pro.idorsia.uk.
The content of this website contains promotional information for UK healthcare professionals and is managed by Idorsia Pharmaceuticals UK Ltd.
UK-DA-01463 | Date of preparation: April 2026
Your resource is ready to download.
Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.
Download will open in a new window.
Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.
You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.
You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.
UK-DA-00445 | Date of preparation: Februrary 2026
Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.
It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.
For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.
This information is intended for UK Healthcare Professionals only.
By entering this site you are confirming that you are a UK Healthcare Professional.
UK-DA-00217 | Date of preparation: February 2026
